miR-17-20a targets and inhibits Calcipressin-3 (RCAN3, that inhibits tumor progression29 and HUVEC proliferation30) to increase ischemic endothelial angiogenic capacity and promote M2-like phenotype in ischemic macrophages. Here, RCAN3 is linked to neoplasm.